Clinical Trials Logo

Pulmonary Arterial Hypertension clinical trials

View clinical trials related to Pulmonary Arterial Hypertension.

Filter by:

NCT ID: NCT03528902 Not yet recruiting - Hypertension Clinical Trials

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

T3PAH
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated, and its impact on functional condition and selected biomarkers. Changes in tricuspid annular plane systolic excursion (TAPSE) and other parameters determined by transthoracic echocardiography will be evaluated as well as changes in additional metrics such as six minute walk test distance, quality of life assessments, and hormone levels.

NCT ID: NCT03522935 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Subcutaneous Elafin in Healthy Subjects

Start date: May 15, 2018
Phase: Phase 1
Study type: Interventional

A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects. The purpose of this study is to assess Elafin that is being developed for treatment of PAH. Elafin inhibits elastase, an enzyme that is increased in pulmonary hypertension and is a major factor in the development of PAH. Elafin will be administered subcutaneously daily for 7 days in normal healthy subjects followed over a 28 day time period.

NCT ID: NCT03497689 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Start date: June 2018
Phase: Phase 4
Study type: Interventional

This is a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in prostanoid-naive subjects with pulmonary arterial hypertension (PAH).

NCT ID: NCT03496207 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

PULSAR
Start date: June 2018
Phase: Phase 2
Study type: Interventional

Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011) relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible participants will receive study treatment for 6 months in the double-blind Treatment Period, and then will be eligible to enroll into an 18-month Extension Period during which all participants will receive sotatercept. All treated patients will be also undergo follow-up period after last treatment.

NCT ID: NCT03492177 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Start date: June 30, 2018
Phase: Phase 2
Study type: Interventional

Selexipag is available for the treatment of pulmonary arterial hypertension (PAH) in adults in various countries. The efficacy of selexipag to delay disease progression was shown in a previous pivotal study conducted in 1156 adult patients with PAH. Given the similarities in the functional changes of PAH in children and adults, it is expected that children suffering from PAH could benefit from treatment with selexipag. The aim of the present study is to confirm the doses of selexipag to be used in pediatric patients with PAH older than 2 years. To fulfill this aim, blood levels of selexipag (pharmacokinetic assessments) as well as the safety, and tolerability of selexipag in children with PAH will be assessed.

NCT ID: NCT03489005 Recruiting - Heart Failure Clinical Trials

Effect of BIA 5 1058 on Cardiac Repolarization

Start date: April 2018
Phase: Phase 1
Study type: Interventional

The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)

NCT ID: NCT03476629 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension.

PAH
Start date: January 10, 2016
Phase: N/A
Study type: Interventional

Although there has been some progress in pharmacological management of PAH, limited functional capacity and low survival still persist, but there is evidence that exercise training can be accomplished without adverse effects or damage to cardiac function and pulmonary hemodynamics. Specifically, improvements in symptoms, exercise capacity, peripheral muscle function and quality of life. Training programs need to be better studied and well defined, and their physiological effects during physical training and functional capacity. The aim of this study is to compare the effects of different training exercises on physical performance indicators.

NCT ID: NCT03464864 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Start date: March 9, 2018
Phase: Phase 1
Study type: Interventional

A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

NCT ID: NCT03422328 Enrolling by invitation - Clinical trials for Pulmonary Arterial Hypertension

A Clinical Study in France to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Arterial Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

Start date: April 4, 2018
Phase: Phase 3
Study type: Interventional

The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) who were previously treated with macitentan in clinical studies.

NCT ID: NCT03401476 Enrolling by invitation - Clinical trials for Pulmonary Arterial Hypertension

Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension

Start date: May 8, 2017
Phase: Phase 2
Study type: Interventional

Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic. In one survey of 315 patients with PAH, sixty-eight percent had moderate or severe dyspnea on exertion and 40% had a profound and clinically significant deficit in quality of life. Palliative care is being increasingly investigated in life-limiting cardiovascular diseases to alleviate symptoms. In PAH, its implementation is frequently delayed until end-of-life. Opioids are a common palliative care intervention, however the efficacy and safety of opioids for symptom relief in PAH has not been evaluated.